Patents by Inventor Flavio Curnis

Flavio Curnis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NGR CONJUGATES AND USES THEREOF
    Publication number: 20230181719
    Abstract: The present invention relates to a conjugate comprising a first peptide of sequence CNGRCG (SEQ ID NO: 1) linked to the N-terminus of a protein and a compound X linked to the N-terminus of said peptide and to related medical uses.
    Type: Application
    Filed: March 19, 2021
    Publication date: June 15, 2023
    Applicant: OSPEDALE SAN RAFFAELE S.R.L.
    Inventors: Flavio CURNIS, Angelo CORTI, Andrès J. M. FERRERI
  • CHROMOGRANIN A-DERIVED PEPTIDES AND USES THEREOF
    Publication number: 20220402980
    Abstract: The present invention refers to chromogranin A-derived peptides that are potent dual ligands for integrins ?v?6 and av?8, their therapeutic and diagnostic uses and relative compositions.
    Type: Application
    Filed: November 16, 2020
    Publication date: December 22, 2022
    Applicant: OSPEDALE SAN RAFFAELE S.R.L.
    Inventors: Flavio CURNIS, Angelo CORTI, Giovanna MUSCO, Michela GHITTI, Francesca NARDELLI, Alessandro GORI
  • Immunoconjugates for the treatment of tumours
    Patent number: 9782496
    Abstract: A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: October 10, 2017
    Assignee: MolMed SpA
    Inventors: Angelo Corti, Flavio Curnis
  • Peptides for inhibiting tumor growth
    Patent number: 9561289
    Abstract: A product comprising a peptide that comprises a motif selected from a group consisting of isoDGR, NGR and DGR, wherein the peptide cyclized by joining the N- and C-termini of its main chain and wherein the cyclic peptide is joined to albumin.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 7, 2017
    Assignee: OSPEDALE SAN RAFFAELE SRL
    Inventors: Angelo Corti, Flavio Curnis
  • Immunoconjugates for the Treatment of Tumours
    Publication number: 20160074537
    Abstract: A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.
    Type: Application
    Filed: July 29, 2015
    Publication date: March 17, 2016
    Inventors: Angelo Corti, Flavio Curnis
  • Immunoconjugates for the treatment of tumours
    Patent number: 9119886
    Abstract: A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: September 1, 2015
    Assignee: MolMed SpA
    Inventors: Angelo Corti, Flavio Curnis
  • PEPTIDES
    Publication number: 20150045302
    Abstract: A product comprising a peptide that comprises a motif selected from a group consisting of isoDGR, NGR and DGR, wherein the peptide cyclised by joining the N- and C-termini of its main chain and wherein the cyclic peptide is joined to albumin.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 12, 2015
    Inventors: Angelo Corti, Flavio Curnis
  • PEPTIDES COMPRISING AN ISODGR MOTIF
    Publication number: 20110076234
    Abstract: Disclosed herein are peptides which include an isoDGR motif and which selectively inhibit ?v?3 integrin. In some embodiments, the isoDGR motif results from the deamidation of an NGR motif.
    Type: Application
    Filed: July 14, 2010
    Publication date: March 31, 2011
    Inventors: ANGELO CORTI, FLAVIO CURNIS
  • Immunoconjugates for the Treatment of Tumours
    Publication number: 20100310506
    Abstract: A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.
    Type: Application
    Filed: April 30, 2010
    Publication date: December 9, 2010
    Applicant: MolMed Spa
    Inventors: Angelo Corti, Flavio Curnis
  • Peptides comprising an isoDGR motif
    Patent number: 7795386
    Abstract: Disclosed herein are peptides which include an isoDGR motif and which selectively inhibit ?v?3 integrin. In some embodiments, the isoDGR motif results from the deamidation of an NGR motif.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: September 14, 2010
    Assignees: Molmed SpA, Fondazione Centro San Raffaele del Monte Tabor
    Inventors: Angelo Corti, Flavio Curnis
  • Conjugation Product
    Publication number: 20090068106
    Abstract: A peptide which selectively inhibits ?v?3 integrin which comprises the deamidation product of a peptide comprising the NGR motif.
    Type: Application
    Filed: December 21, 2005
    Publication date: March 12, 2009
    Inventors: Angelo Corti, Flavio Curnis
  • Fusions of cytokines and tumor targeting proteins
    Publication number: 20050074426
    Abstract: A conjugate of a cytokine and a tumor targeting moiety (TTM) with the provisos that when cytokine is TNF-?, TNF-? or IFN-?, the TTM is other than a CD13 ligant; when the cytokine is IL-12, the TTM is other than an antiboy to fibronectin; when the cytokine is TNF, the TTM is other than an antibody to the transferrin receptor, and when the cytokine is TNF, IFN-?, or IL-2 the antibody is other than an antibody to the TAG72 antigen.
    Type: Application
    Filed: April 30, 2003
    Publication date: April 7, 2005
    Inventors: Angelo Corti, Flavio Curnis
  • Immunoconjugates for the treatment of tumours
    Publication number: 20050033026
    Abstract: A pharmaceutical composition comprising a conjugate of a cytokine and a tumor targeting moiety (TTM) and a pharmaceutically acceptable excipient, wherein the cytokine is present in an amount which does not induce a negative feedback mechanism.
    Type: Application
    Filed: April 30, 2003
    Publication date: February 10, 2005
    Inventors: Angelo Corti, Flavio Curnis